Prediction of changes in the clinical pharmacokinetics of basic drugs on the basis of octanol-water partition coefficients

被引:18
作者
Ishizaki, J [1 ]
Yokogawa, K [1 ]
Nakashima, E [1 ]
Ichimura, F [1 ]
机构
[1] KANAZAWA UNIV, GRAD SCH PHARMACEUT SCI, PHARMACOL & PHARMACEUT DEPT, KANAZAWA, ISHIKAWA 920, JAPAN
关键词
D O I
10.1111/j.2042-7158.1997.tb06108.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A physiologically based pharmacokinetic model for basic drugs has been established on the basis of acl octanol- partition coefficients of the non-ionized, unbound drugs (P-oct). The parameters for the-physiological model in man were estimated from a regression equation obtained for the relationships between the P-oct and the tissue-plasma partition coefficient, the hepatic Intrinsic clearance (CLint,h) and the blood-to-plasma concentration ratio in rabbits, The plasma concentrations observed after intravenous administration of ten basic drugs (3.2 mg kg(-1)) to rabbits agreed with the levels predicted using the physiological model (r = 0.710-0.980). In man, the predicted plasma concentrations of basic drugs were in good agreement with reported values (r = 0.729-0.973), except for diazepam and pentazocine. Variations in plasma and brain-concentration profiles of clomipramine and nitrazepam in various disease states were simulated using the model. We assumed that the changes in unbound fraction of drug in serum (f(p)), CLint,h and the hepatic blood flow rate were from 0.25- to 4-fold that of the control and that fat volume changed by 0.2- to 5-fold. With regard to changes in f(p), we predicted that the brain-plasma concentration ratio of clomipramine was 1.5- to 25-fold that of the control. 24 h after intravenous administration, although the variations in the plasma concentration-time profiles were less marked. Plasma concentrations predicted for several basic drugs were in good agreement with reported values and this physiological model could be useful for predicting drug-disposition kinetics in man.
引用
收藏
页码:762 / 767
页数:6
相关论文
共 31 条
[1]  
ARENDT R, 1982, ARZNEIMITTEL-FORSCH, V32-1, P453
[2]  
ARKY R, 1996, PHYSICIANS DESK REFE, P803
[3]   SEVERITY OF CIRRHOSIS AND THE RELATIONSHIP OF ALPHA-1-ACID GLYCOPROTEIN CONCENTRATION TO PLASMA-PROTEIN BINDING OF LIDOCAINE [J].
BARRY, M ;
KEELING, PWN ;
WEIR, D ;
FEELY, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (03) :366-370
[4]  
BENET LZ, 1995, PHARMACOL BASIS THER, P1712
[5]   COMPARATIVE PHARMACOKINETICS OF BENZODIAZEPINES IN DOG AND MAN [J].
BOXENBAUM, H .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1982, 10 (04) :411-426
[6]   PHARMACOKINETICS OF HALOPERIDOL AND REDUCED HALOPERIDOL IN CHINESE SCHIZOPHRENIC-PATIENTS AFTER INTRAVENOUS AND ORAL-ADMINISTRATION OF HALOPERIDOL [J].
CHANG, WH ;
LAM, YWF ;
JANN, MW ;
CHEN, H .
PSYCHOPHARMACOLOGY, 1992, 106 (04) :517-522
[7]   PHARMACOKINETICS OF HALOPERIDOL IN PSYCHOTIC-PATIENTS [J].
CHENG, YF ;
PAALZOW, LK ;
BONDESSON, U ;
EKBLOM, B ;
ERIKSSON, K ;
ERIKSSON, SO ;
LINDBERG, A ;
LINDSTROM, L .
PSYCHOPHARMACOLOGY, 1987, 91 (04) :410-414
[8]   HUMAN WHOLE-BLOOD AND PAROTID-SALIVA CONCENTRATIONS OF ORAL AND INTRAMUSCULAR PROMETHAZINE [J].
DIGREGORIO, GJ ;
RUCH, E .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (12) :1457-1459
[9]   THE BIOAVAILABILITY OF ORAL AND PARENTERAL CHLORIMIPRAMINE (ANAFRANIL) [J].
EVANS, LEJ ;
BETT, JHN ;
COX, JR ;
DUBOIS, JP ;
VANHEES, T .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY, 1980, 4 (03) :293-302
[10]  
GREENBLATT DJ, 1989, J PHARMACOL EXP THER, V250, P134